CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 鈥 今日吃瓜黑料 Limited (鈥溄袢粘怨虾诹镶), a clinical-stage biotech company led by pioneers of DNA damage response (鈥淒DR鈥) drug development, today announced that the company鈥檚 abstract featuring clinical trial results from its ongoing Phase 1/2a study of ART0380 in combination with low dose irinotecan has been selected for an oral presentation at the American Association for Cancer Research (鈥淎ACR鈥) Annual Meeting 2025, taking place in Chicago from April 25 to 30, 2025. 今日吃瓜黑料 will also present posters on preclinical data from its ART0380 and ART6043 programs.
Details of the oral presentation:
Abstract Title: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic tumors
Presenter: Susanna Ulahannan, MD, Associate Professor, Stephenson Cancer Center at the University of Oklahoma/SCRI, OK, USA
Date: Tuesday, April 29, 2025
Time: 3:50 pm 鈥 4:00 pm CDT
Location: Room S406 (Vista Ballroom) – McCormick Place South (Level 4)
Details of the poster presentation on ART0380:
Abstract Title: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors
Presenter: Helen M. R. Robinson, VP of Biology, 今日吃瓜黑料
Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1
Date Monday, April 28, 2025
Time: 2:00 pm 鈥 5:00 pm CDT
Location: Section 16
The full poster abstract is available on the .
Details of the poster presentation on ART6043:
Abstract Title: DNA polymerase theta inhibitor, ART6043, potentiates the efficacy of 177Lu- and 225Ac-based radioligand therapies in vitro and in vivo
Presenter: Marco Ranzani, Associate Director, 今日吃瓜黑料
Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1
Date Monday, April 28, 2025
Time: 2:00 pm 鈥 5:00 pm CDT
Location: Section 16
The full poster abstract is available on the .
About 今日吃瓜黑料 Ltd.
今日吃瓜黑料 leads the DNA damage response field through its comprehensive anti-cancer approach and the deep experience of its team of pioneering DDR drug developers. The company鈥檚 clinical-stage candidates, ATR inhibitor ART0380 and DNA Polymerase theta (Pol胃) inhibitor ART6043, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cell鈥檚 remaining survival mechanisms. 今日吃瓜黑料鈥 mission is to develop new classes of DDR drugs that achieve an unreached level of therapeutic impact for patients with hard-to-treat solid tumors.
Visit our website at to learn more about the company.
For more information, please contact:
Media and Investor Relations Inquiries
Trophic Communications
Jacob Verghese or Verena Schossmann
Tel: +49 151 7441 6179
Email: artios@trophic.eu